Exhibit 99.1

Immuron CEO, Steven Lydeamore to present at Coffee Microcaps Melbourne, Australia, May 2 , 2023 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made today in Melbourne at Coffee Microcaps Conference by our Chief Executive Officer, Steven Lydeamore . This release has been authorised by the directors of Immuron Limited . - - - END - - - COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com

About Travelan® Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce . Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea - causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea . In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709 ) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro - intestinal disorders and is antimicrobial . In Canada, Travelan® is a licensed natural health product (NPN 80046016 ) and is indicated to reduce the risk of Travelers’ Diarrhea . In the U . S . , Travelan® is sold as a dietary supplement for digestive tract protection . About Travelers’ diarrhea Travelers’ diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role . Campylobacter spp . are also responsible for a significant proportion of cases . The more serious infections with Salmonella spp . the bacillary dysentery organisms belonging to Shigella spp . and Vibrio spp . (the causative agent of cholera) are often confused with travelers’ diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable . About Immuron Immuron Limited (ASX : IMC, NASDAQ : IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases . For more information visit : http : //www . immuron . com FORWARD - LOOKING STATEMENTS : This press release may contain “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 , each as amended . Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts . Forward - looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value . Factors that could cause actual results to differ materially from those currently anticipated include : risks relating to our growth strategy ; our ability to obtain, perform under and maintain financing and strategic agreements and relationships ; risks relating to the results of research and development activities ; risks relating to the timing of starting and completing clinical trials ; uncertainties relating to preclinical and clinical testing ; our dependence on third - party suppliers ; our ability to attract, integrate and retain key personnel ; the early stage of products under development ; our need for substantial additional funds ; government regulation ; patent and intellectual property matters ; competition ; as well as other risks described in our SEC filings . We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward - looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law .

1 INVESTOR PRESENTATION COFFEE MICROCAPS 2 MAY, 2023 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC

2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections . Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward - looking statements . Although Immuron believes the forward - looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercializing technology . As a result, actual results could materially differ from those expressed or forecasted in the forward - looking statements . The forward - looking statements made in this presentation relate only to events as of the date on which the statements are made . Immuron will not undertake any obligation to release publicly any revisions or updates to these forward - looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority . YTD FY 2023 results in this presentation are subject to audit review . SAFE HARBOR STATEMENT

3 EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview • Two commercially available oral immunotherapeutic products – Travelan® and Protectyn® • 4 clinical programs – Travelan® (IMM - 124E), CampETEC, IMM - 529, Travelan® (consumer product) • Market capitalisation of A$18.67m as of 20 April 2023 with cash & cash equivalates balance of A$18.5m as of 31 Dec 2022 • Travelan® (IMM - 124E) - IND filed and received FDA Authorization to proceed under IND 029087 a • CampETEC – toxicology study report completed and submitted to FDA • Travelan® Uniformed Health Services University P2TD IMM - 124E field clinical trial recruitment reaches 300 • 35% of target 868 participants recruited • Immuron’s own shopfront on amazon.com for Travelan® set up for USA market • Launch pending establishing necessary safety stock level • Working towards relaunch of Travelan® into Canadian retail pharmacy in FY24 • Submitted for range review to major pharmacy chain • FY23 YTD 14 April 2023 revenue of A$1.78m, up 233% YTD on pcp – Australian sales contributing A$1.18m • Evaluating options to enter Asian and European markets through distributors • Evaluating options to add to marketed products portfolio in FY24 Recent Business Updates Results & Outlook a ASX Release link in appendix. YTD FY2023 results in this presentation are subject to audit review.

4 Australia USA Canada Retail Pharmacy B2B E - commerce DISTRIBUTION CAPABILITY Key Commentary • The Australian retail network includes over 3,500 pharmacies • In the USA, the key B2B customer is Passport Health - the largest network of travel medicine clinics • Immuron’s own shopfront on amazon.com will be introduced in the USA during FY23 • Re - entry into retail pharmacies in USA will be explored in FY24 • In Canada, we are working towards a relaunch into retail pharmacy in FY24 • We are exploring options to expand B2B business in airlines, cruise ships, health & wellness segments • We are evaluating options to enter Asian and European markets through distributors Established Developing ANB Canada Ontario, Canada Distributes to all provinces of Canada Immuron Limited Vancouver, BC, Canada Immuron Inc. New York, USA RJW Logistics Chicago, USA Distributes to all states of USA Immuron Limited Melbourne, Australia Distributes to all states of Australia and to distributors in USA and Canada

5 ADDRESSABLE MARKET & INDUSTRY OVERVIEW Billion Dollar Market Travelers diarrhea treatment market is large and growing at a CAGR of ~7% Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveler’s diarrhea*** * IQVIA Consumer Health Category QuickView MAT Q1 2019 ** IMC Company Report - Travelan Market Analysis 2019 *** Centers for Disease Control and Prevention Yellow Book ~$15b+ Immuron’s products are a subset of the global digestive health market, which a multi - billion - dollar market* ~7% CAGR Travelers diarrhea treatment market is large and growing at a CAGR of ~7% over 2019 - 2022* Travelan® has large market potential given that acute diarrhea affects millions of travelers each year $83m Based on US annual travel numbers and a penetration rate of 15%, the market potential is estimated at $83m** $50m Based on EU travel numbers and a penetration rate of 15%, the market potential is estimated at $50m** $1.7b Clostridioides difficile infections (CDIs) to grow to almost $1.7 billion by 2026, according to GlobalData

6 Key Commentary • Strong start to Q4 2023 (to 14 April 2023) • $320k Net Sales; up 233% YTD on pcp • Supply chain capacity addressed by contracting another packaging supplier • Strong sales for Travelan®, well above pre - pandemic levels, may results in short term stock outages in some wholesalers and pharmacies over the next month • Building stock to allow accelerated growth in international markets SALES | YEAR TO DATE | 14 TH APRIL 2023 * YTD FY2023 results in this presentation are subject to audit review. A$000s Profit & Loss FY23 YTD 14 April 2023 FY22YTD 14 April 2022 Var % Australian Sales $ 1,184 $ 137 764% Rest of World Sales $ 595 $ 397 50% Total Revenue $ 1,779 $ 534 233%

7 M&A Strategy • By pursuing growth through M&A of a fragmented market, IMC believes that it will be able to increase market geographies, sales channels and penetration driving revenue growth and ultimately shareholder value • Our M&A Key Criteria focusses on: Expand existing customer base Cost & Earnings Synergies Strength of IP and Management Distribution network and sales & marketing by each product BUSINESS POSITIONED FOR ORGANIC GROWTH AND NEW M&A STRATEGY Organic Growth Strategy • Focus on commercialised products and near - term development extensions, including: 1 • Travelan®: • Sales expansion across target geographies • Growth in distribution network and sales & marketing initiatives • Product development (new formulations including once daily dosing) e.g. FDA approval 2 • Protectyn®: • Sales expansion across target geographies • Growth in distribution network and sales & marketing initiatives • Product development and broader applications 1 • Expand market verticals & product offering 2 • 3 • 4 • 5 •

8 STEP 1 STEP 2 STEP 3 FINAL PRODUCT Development of Highly Specific Vaccines Isolation of Hyperimmune antibody - rich bovine colostrum Oral Antimicrobial therapeutics without drawbacks of antibiotics Toxin Neutralization + Clearance of targeted gut pathogens TECHNOLOGY PLATFORM Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. x x x x x x Reduce occurrence and reduce/relieve diarrhoea Reduce/relieve abdominal cramping Reduce/relieve gastrointestinal pain Assists repair of gastrointestinal/gut wall lining Enhance/promote immune defence Enhance/promote health liver function Australian Permitted indications; these statements have not been evaluated by the Food and Drug Administration (FDA)

9 Compound or brand name Partner Phase I Phase II Phase III Market Travelan® Uniformed Ser University vices CampETEC Naval Med Research C ical ente r • US Department of Defense grant of US$4.45 million to examine a dosing regimen for Travelan® more suited for use by the military b o Market evaluation by Lumanity confirms the Traveler’s Diarrhea market opportunity for IMM - 124E (Travelan®) c o IMM - 124E (Travelan®) IND was approved by the FDA in 2H2022 a o Clinical trials anticipated to commence in 1H2023 • Market evaluation by Lumanity confirms the Clostridioides difficile market opportunity for IMM - 529 d o 600mg solid dose active formulation development completed o Project strategy and budget to be approved by the Immuron Board before initiating clinical trials • Travelan® - Uniformed Services University has recruited more than 35% of participants in a randomized clinical trial with Travelan® to evaluate the effectiveness for prophylaxis during deployment or travel to a high traveler’s diarrhea risk region o Estimated Study Primary Completion Date – 30 July 2023 o Estimated Study Completion Date – 31 December 2023 • Naval Medical Research Center Clinical Trials of CampETEC in campylobacter and enterotoxigenic E.coli (ETEC) f o Toxicology study submitted to FDA – 8 March 2023 o Written Guidance received from FDA – 10 March 2023 o Response letter submitted – 5 April 2023 o Anticipate FDA feedback in May 2023 STATUS OF PRODUCT PORTFOLIO AND KEY MILESTONES *Further information on the clinical programs can be found on slide 11 Compound or brand name Indication Phase I Phase II Phase III Market IMM - 124E Travelan® Traveler’s Diarrhea ETEC challenge IMM - 529 Clostridioides difficile Infection & Recurrence Immuron’s Clinical Programs Our Partners’ Clinical Programs a ,b,c,d,f ASX Release links in appendix

10 • Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need • Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80 % protection against the development of diarrhea . • If base case efficacy targets are reached, IMM - 124E would mostly be used by travelers going to the highest risk areas (e.g., rural Central America/Asia/Africa). • Based on the estimated market size and pricing, the base case yearly revenue in USA for IMM - 124 E is projected at US $ 102 M . • Reaching higher efficacy goals could broaden use. IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT Lumanity* Opportunity Assessment for IMM - 124E b Lumanity Opportunity Assessment for IMM - 529 c Compound or brand name Indication Phase I Phase II Phase III Market IMM - 124E - Travelan® Traveler’s Diarrhea ETEC challenge IMM - 529 Clostridioides difficile Infection & Recurrence • Infectious disease experts reacted favorably to the IMM - 529 MOA, and its unique ability to target three elements of the rCDI infection – the spores, vegetative cells, and Toxin B • Non - microbiome approaches (such as IMM - 529) are still appealing to experts, who noted that clinical trial efficacy (reduction in relapse rate) and cost/access will be the key drivers of clinical use in recurrent patients, not mechanism of action • Based on the estimated market size, anticipated payer restrictions, pricing, and competition, base case yearly revenue in USA for IMM - 529 is conservatively projected at $93M for the target patient population (limited to 2 nd recurrence and later based on trial design and payer coverage) • Positioning IMM - 529 at the point of second relapse and/or efficacy targets could lead to higher uptake. • Lumanity, a leading lifescience consulting company: https://lumanity.com/company/our - story /

11 KEY MILESTONES ANTICIPATED TO DRIVE VALUE 2H 2022 1H 2023 2H 2023 1H 2024 Travelan® • FDA IND 1 approved for single daily dose IMM - 124E ETEC 2 CHIM 3 clinical trial a • IRB Approval 4 • Initiate IMM - 124E ETEC CHIM clinical trial • Topline results for IMM - 124E ETEC CHIM clinical trial • Clinical Study Report CampETEC • Submitted Response Letter to FDA Clinical Hold f • Immuron sponsored Toxicology study - completed • Toxicology Study Report • FDA feedback to clinical hold response letter • Initiate NMRC 5 CampETEC ETEC CHIM clinical trial • Initiate NMRC CampETEC Campylobacter CHIM clinical trial • Topline results for NMRC CampETEC ETEC CHIM clinical trial • Topline results for NMRC CampETEC Campylobacter CHIM clinical trial IMM - 529 • 600 mg solid dose active formulation development • Project strategic planning and budget development • IMM - 529 cGMP manufacture 6 • IMM - 529 IND Pre - IND submission 6 • IMM - 529 IND submission 6 • Initiate IMM - 529 phase 2 CDI clinical trial 6 Travelan® • USU 7 P2TD IMM - 124E field clinical trial recruitment commencement e • 35% of 868 participants recruited • Primary Study Completion • Study Completion Completed; 1. Investigational New Drug; 2. Enterotoxigenic E.coli ; 3. controlled human infection model; 4. Institutional Review Board; 5. Naval Medical Research Center; 6. Project strategy and budget to be approved by the Immuron Board; 7. Uniformed Health Services University of the Health Sciences; a,h,g ASX Release links in appendix

Steven Lydeamore Chief Executive Officer Immuron Limited 2 May 2023 Contact Information: Phone: Australia: +613 8892 4854 Email: steve@immuron.com

13 Substantial Shareholders * Holder Units % of CSO BNY Mellon Asset Management 77,903,505 34.2 % Management & Board 6,904,554 3.0 % Authentics Australia Pty. Ltd. 6,000,000 2.6 % Grandlodge 3,846,712 1.7 % • Shareholder Base: • Large retail shareholder base in US and Australia • BNY Mellon Asset Management (American Depository Shares) holds 34% stake • Board and management aligned with shareholders, holding 3% stake CORPORATE SNAPSHOT *As at 21 April 2023 Financial Snapshot Shares on Issue 227,798,346 Total Options 12,879,720 Last Traded Price $0.082 52 week High/Low 0.125/0.067 Market Cap (20 Apr 23) $18.67m Cash & Cash Equivalents (as at 31 Dec 22) $18.5m

14 SCIENTIFIC REFERENCES Travelan® (IMM - 124E) Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan as a broad Spectrum anti - bacterial Immuron Limited, 29 April, 2011 Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler’s diarrhea US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 4 September, 2019 Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared to placebo and demonstrated a significant clinical benefit US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 5 September, 2018 Travelan® able to bind and was reactive to 60 clinical isolates of each bacteria, Campylobacter, ETEC, and Shigella US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 30 January, 2017 Efficacy of hyperimmune bovine colostrum against shigellosis in rhesus macaque (Macaca mulatta), and bioactivity of HBC against common enteric pathogens Islam et al., 2020. Submitted to mSphere, American Society for Microbiology Bioactive Immune Components of Travelan® Clin Vaccine Immunol 24:e00186 - 16. https://doi.org/10.1128/CVI.00186 - 16 Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM - 124E) has a non - detrimental effect on gut microbial communities in unchallenged mice Rachele Gore, Mitra Mohsenipour, Jennifer L Wood, Gayathri K Balasuriya, Elisa L Hill - Yardin, Ashley E Franks Administration of the Hyper - immune Bovine Colostrum Extract IMM - 124E Ameliorates Experimental Murine Colitis Journal of Crohn's and Colitis, Volume 13, Issue 6, June 2019, Pages 785 – 797, https://doi.org/10.1093/ecco - jcc/jjy213 IMM - 529 Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598 - 017 - 03982 - 5

15 ASX RELEASES REFERENCED Ref Slide statement ASX Release a Travelan® (IMM - 124E) IND filed with and approved by FDA Immuron Receives FDA Approval for Travelan IND Application b US Department of Defense grant of US$4.45 million to examine a dosing regimen for Travelan® more suited for use by the military Immuron awarded A$6.2 million US DoD funding for Travelan c Market evaluation by Lumanity confirms the Traveler’s Diarrhea market opportunity for IMM - 124E (Travelan®) AGM Presentation d Market evaluation by Lumanity confirms the Clostridioides difficile market opportunity for IMM - 529 AGM Presentation e Travelan® - Uniformed Services University has recruited more than 20% of participants in a randomized clinical trial with Travelan® to evaluate the effectiveness for prophylaxis during deployment or travel to a high traveler’s diarrhea risk region US DOD Travelan Clinical Recruitment Milestone f Naval Medical Research Center Clinical Trials of CampETEC in campylobacter and enterotoxigenic E.coli (ETEC) Immuron and US NMRC respond to CampETEC FDA Clinical Hold